Evidence map›Paper›PMID 31161433›Full record

ArticleMedical oncology (Northwood, London, England)2019

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yunami Yamada, Hironori Fujii, Koichi Ohata, Hiroko Kato-Hayashi, Daichi Watanabe, Takuma Ishihara, Shinya Uemura, Takuji Iwashita, Hisashi Imai, Nobuhisa Matsuhashi and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yunami YamadaDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Hironori FujiiDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan. h_fujii@gifu-u.ac.jp.ORCID http://orcid.org/0000-0003-0944-7290
Koichi OhataDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Hiroko Kato-HayashiDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Daichi WatanabeDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Takuma IshiharaGifu University Hospital Innovative and Clinical Research Promotion Center Gifu University, Gifu, 501-1194, Japan.
Shinya UemuraFirst Department of Internal Medicine, Gifu University Hospital, Gifu, 501-1194, Japan.
Takuji IwashitaFirst Department of Internal Medicine, Gifu University Hospital, Gifu, 501-1194, Japan.
Hisashi ImaiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, 501-1193, Japan.
Nobuhisa MatsuhashiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, 501-1193, Japan.
Takao TakahashiDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, 501-1193, Japan.
Tadashi SugiyamaLaboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.
Masahito ShimizuFirst Department of Internal Medicine, Gifu University Hospital, Gifu, 501-1194, Japan.
Kazuhiro YoshidaDepartment of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu, 501-1193, Japan.
Akio SuzukiDepartment of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Japan.
Gifu University Hospital · JPGifu University · JPGifu Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irinotecan is effective for the treatment of metastatic colorectal cancer (mCRC) and advanced pancreatic cancer (aPC). However, these treatments are often limited due to the incidence of severe neutropenia. We identified risk factors for severe neutropenia in patients with mCRC or aPC, receiving irinotecan-based chemotherapy regimens. The study selected 104 patients (mCRC: 53 and aPC: 51) who received irinotecan-based chemotherapy between January 2014 and May 2018 and who were included in the present study. The initial dose of irinotecan was 150 mg/m

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBilirubinFemaleFluorouracilHumansIncidenceIrinotecanLeucovorinMaleMiddle AgedNeutropeniaOxaliplatinProportional Hazards ModelsBilirubinFluorouracilfolfirinoxIrinotecanLeucovorinOxaliplatinAdvanced pancreatic cancerHigh level of total bilirubinIrinotecanMetastatic colorectal cancerModified FOLFIRINOXSevere neutropenia

Identifiers

PMID31161433
OpenAlexW2948268532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.